» Articles » PMID: 19166485

Triage of Women with Equivocal or Low-grade Cervical Cytology Results: a Meta-analysis of the HPV Test Positivity Rate

Overview
Journal J Cell Mol Med
Date 2009 Jan 27
PMID 19166485
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Consistent evidence underlines the utility of human papillomavirus (HPV) DNA testing in the management of women with equivocal cervical cytological abnormalities, but not in case of low-grade lesions. We performed a meta-analysis including studies where the high-risk probe of the Hybrid Capture-II is used to triage these two cytological categories. The triage test-positivity rate reflects the colposcopy referral workload.Data were pooled on the HPV test positivity rate in women with atypical squamous cells of undetermined significance (ASCUS/ASC-US) or low-grade squamous intraepithelial lesions (LSIL), derived from different cytological classification systems. The meta-analysis was restricted to studies, published between 1991 and 2007. A random-effect model was applied for meta-analytical pooling and the influence of covariates on the HPV positivity rate was analyzed by meta-regression. The variation by age was assessed within individual studies since age strata were not defined uniformly. On an average, 43% (95% CI: 40-46%) of women with ASCUS/ASC-US were high-risk HPV positive (range 23-74%). In women with LSIL, the pooled positivity rate was 76% (95% CI: 71-81%; range 55-89%). In spite of considerable inter-study heterogeneity, the difference in HPV positivity between the two triage groups was large and highly significant: 32% (95% CI: 27-38%). HPV rates dropped tremendously as age and cutoffs of test positivity increased. Other factors (cytological classification system, country, continent, collection method and year of publication) had no statistically significant impact, except in LSIL triage where HPV positivity was significantly lower in European compared to American studies. Women with LSIL, especially younger women, have high HPV positivity rates suggesting limited utility of reflex HPV triaging these cases. Research is needed to identify more specific methods to triage women with low-grade squamous cervical lesions.

Citing Articles

13-Type HPV DNA Test versus 5-Type HPV mRNA Test in Triage of Women Aged 25-33 Years with Minor Cytological Abnormalities-6 Years of Follow-Up.

Rad A, Sorbye S, Brenn T, Tiwari S, Lochen M, Skjeldestad F Int J Environ Res Public Health. 2023; 20(5).

PMID: 36901129 PMC: 10002392. DOI: 10.3390/ijerph20054119.


Role of Dual-Staining p16/Ki-67 in the Management of Patients under 30 Years with ASC-US/L-SIL.

Secosan C, Pasquini A, Zahoi D, Motoc A, Lungeanu D, Balint O Diagnostics (Basel). 2022; 12(2).

PMID: 35204494 PMC: 8870853. DOI: 10.3390/diagnostics12020403.


Comparison of CINtec PLUS cytology and cobas HPV test for triaging Canadian patients with LSIL cytology referred to colposcopy: A two-year prospective study.

Gilbert L, Ratnam S, Jang D, Alaghehbandan R, Schell M, Needle R Cancer Biomark. 2022; 34(3):347-358.

PMID: 35001877 PMC: 9535599. DOI: 10.3233/CBM-210366.


Liquid-Based Screening Tests Results: HPV, Liquid-Based Cytology, and P16/Ki67 Dual-Staining in Private-Based Opportunistic Cervical Cancer Screening.

Trzeszcz M, Mazurec M, Jach R, Mazurec K, Jach Z, Kotkowska-Szeps I Diagnostics (Basel). 2021; 11(8).

PMID: 34441354 PMC: 8394579. DOI: 10.3390/diagnostics11081420.


Use of extended HR-HPV Genotyping in improving the Triage Strategy of 2019 ASCCP recommendations in Women with positive HR-HPV diagnosis and Simultaneous LSIL Cytology Results.

Xue H, Gao H, Zheng J, Chen Y, Chen J, Pan D J Cancer. 2021; 12(14):4332-4340.

PMID: 34093833 PMC: 8176432. DOI: 10.7150/jca.55826.


References
1.
Bergeron C, Cas F, Fagnani F, Contrepas A, Wadier R, Poveda J . [Assessment of human papillomavirus testing on liquid-based Cyto-screen system for women with atypical squamous cells of undetermined significance. Effect of age]. Gynecol Obstet Fertil. 2006; 34(4):312-6. DOI: 10.1016/j.gyobfe.2006.02.008. View

2.
Arbyn M, Sasieni P, Meijer C, Clavel C, Koliopoulos G, Dillner J . Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006; 24 Suppl 3:S3/78-89. DOI: 10.1016/j.vaccine.2006.05.117. View

3.
Bergeron C, Jeannel D, Poveda J, Cassonnet P, Orth G . Human papillomavirus testing in women with mild cytologic atypia. Obstet Gynecol. 2000; 95(6 Pt 1):821-7. DOI: 10.1016/s0029-7844(00)00795-x. View

4.
Manos M, Kinney W, Hurley L, Sherman M, Kurman R, Ransley J . Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 1999; 281(17):1605-10. DOI: 10.1001/jama.281.17.1605. View

5.
Kurman R, Henson D, Herbst A, Noller K, Schiffman M . Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA. 1994; 271(23):1866-9. View